Search results
Results from the WOW.Com Content Network
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. [1] [2] [3] The company is the maker of Botox.
Website. www .actavis .com. Actavis Generics[ 1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
Allergan: Off-label promotion of Botox, September 2010. Allergan, the manufacturer of Botox, agreed to a $600 million settlement to resolve all civil and criminal liability surrounding the promotion of Botox for treatment of chronic migraines before FDA review or approval of the drug for such use.
Pharmaceutical company Allergan (AGN) has settled the Department of Justice's criminal and civil charges that it promoted Botox for uses the Food and Drug Administration hadn't approved as safe ...
Sources say the pharmaceutical company that manufactures Botox, Allergan, charges providers around $6-7 per unit, making the average patient cost more like $10-15 per unit (with metropolitan areas ...
The maker of Botox Allergan will be bought by Abbvie in a cash and stock deal valued at about $63 billion. Yahoo Finance's Alexis Christoforous and Brian Sozzi speak to Connor Browne, a portfolio ...
Alan B. Scott. Alan Brown Scott (July 13, 1932 – December 16, 2021 [1]) was an American ophthalmologist specializing in eye muscles and their disorders, such as strabismus (eye misalignment). He is best known for his work in developing and manufacturing the drug that became known as Botox, research described as "groundbreaking" by the ASCRS. [2]
Allergan Inc. (AGN), the maker of the wrinkle-smoother Botox, reported profit fell 58 percent as the recession slowed sales of the frown line drug, as well as sales of eye and beauty products.